M1 macrophages stimulated with low-dose Lipo-MP-LPS may however present reduced anti-tumor effects as some studies showed that low doses of TLR4 agonists may turn macrophages toward a tolerant state and M2 phenotype [54]. The gene discussed is TLR4; the disease is neoplasm.